Literature DB >> 6684553

Cytosine arabinoside transport by human leukaemic cells.

J S Wiley, S P Jones, W H Sawyer.   

Abstract

The membrane transport of cytosine arabinoside (araC) has been studied in blasts freshly isolated from a variety of acute leukaemias. The major fraction of araC influx was facilitated and this fraction was 80-87% at l microM araC and 68-80% at 200 microM araC. Competitive kinetics were observed between araC and deoxycytidine for entry into leukaemic blasts and, moreover, araC influx was blocked by phloretin, a broad-spectrum inhibitor of facilitated transport systems. Kinetic analysis of facilitated araC influx gave KmS which varied over a 10-fold range between patients and which were positively correlated to the Vmax. Nucleoside influx Vmax also varied over an 80-fold range between individuals, although the mean araC transport was 4-fold greater in myeloblasts than in lymphoblasts. Larger transport of araC may explain the greater sensitivity of acute myeloid leukaemia to this drug.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6684553     DOI: 10.1016/0277-5379(83)90029-9

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  17 in total

Review 1.  Membrane transport and the antineoplastic action of nucleoside analogues.

Authors:  F M Sirotnak; J R Barrueco
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

2.  OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues.

Authors:  Christina D Drenberg; Alice A Gibson; Stanley B Pounds; Lei Shi; Dena P Rhinehart; Lie Li; Shuiying Hu; Guoqing Du; Anne T Nies; Matthias Schwab; Navjotsingh Pabla; William Blum; Tanja A Gruber; Sharyn D Baker; Alex Sparreboom
Journal:  Cancer Res       Date:  2017-02-16       Impact factor: 12.701

Review 3.  Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside.

Authors:  R L Capizzi
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

4.  Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells.

Authors:  J C White; J P Rathmell; R L Capizzi
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

5.  Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma.

Authors:  J S Wiley; J Taupin; G P Jamieson; M Snook; W H Sawyer; L R Finch
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

6.  Modulation of the cellular pharmacokinetics of ara-CTP in human leukemic blasts by dipyridamole.

Authors:  J L Yang; J C White; R L Capizzi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia.

Authors:  Deepika Bhatla; Robert B Gerbing; Todd A Alonzo; Heather Conner; Julie A Ross; Soheil Meshinchi; Xiaowen Zhai; Tiffany Zamzow; Parinda A Mehta; Hartmut Geiger; John Perentesis; Stella M Davies
Journal:  Br J Haematol       Date:  2008-11-22       Impact factor: 6.998

8.  Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study.

Authors:  R A Fleming; R L Capizzi; G L Rosner; L K Oliver; S J Smith; C A Schiffer; R T Silver; B A Peterson; R B Weiss; G A Omura
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 9.  Evolution of the arabinosides and the pharmacology of fludarabine.

Authors:  W Plunkett; V Gandhi
Journal:  Drugs       Date:  1994       Impact factor: 9.546

10.  Predicting Drug Interactions with Human Equilibrative Nucleoside Transporters 1 and 2 Using Functional Knockout Cell Lines and Bayesian Modeling.

Authors:  Siennah R Miller; Xiaohong Zhang; Raymond K Hau; Joseph L Jilek; Erin Q Jennings; James J Galligan; Daniel H Foil; Kimberley M Zorn; Sean Ekins; Stephen H Wright; Nathan J Cherrington
Journal:  Mol Pharmacol       Date:  2020-12-01       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.